NEOVACS promotes new immunotherapy articles

NEOVACS has announced that two articles have been published that could be significant to clinical work on active immunotherapy.

Elizabeth Wilson and colleagues published the articles in the Science journal, which presents the results of two mouse models, in which type I interferon restores immune system functions and controls viral titers in mice infected with lymphocytic choriomeningitis virus (LCMV).

Researchers Pameal Odorizzi and John Wherry also indicated that type I interferon blockades could result in a valid therapeutic pathway to treat other conditions.

Pierre Vandepapelière, chief medical officer of NEOVACS, said: “These two articles are very interesting since they highlight the positive role of interferon inhibition in restoring the immune system in the case of chronic viral diseases, as well as the link between interferon signature and the success of treatment.

“We have recently published similar conclusions in Arthritis & Rheumatism for our IFN?-Kinoid immunotherapy in lupus, an autoimmune disease in which Type I interferon plays a negative role.”

At the moment, NEOVACS is developing an anti-interferon immunotherapy in lupus, which looks at the positive effects of immunization with IFN?-Kinoid on certain biomarkers of the disease as well as with expression levels of IFN-induced and lupus-induced genes.

Guy-Charles Fanneau de la Horie, chief executive of NEOVACS, said: “These two publications, in a journal of such scientific repute, bring new validation to our therapeutic approach to the treatment of lupus.

“We believe NEOVACS' IFN?-Kinoid is the only treatment able to induce polyclonal antibodies that effectively neutralize all subtypes of interferon-alpha present in lupus.” 

The representative went on to say that the active immunization pathway has marked advantages over passive immunization with monoclonal antibodies, particularly in chronic conditions.

NEOVACS is focused on the Kinoids active immunotherapy technology platform and is focusing on two active immunotherapies.